Fundraising FoxExSight Ventures — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
ONL Therapeutics is a clinical-stage biopharmaceutical company developing therapies to preserve sight by preventing Fas-mediated death of retinal cells, a cause of vision loss and blindness.
BiotechHealthtechMedical DevicesAnn Arbor, US
David Zacks(Co-Founder and Chief Scientific Officer)inDavid Esposito(President and Chief Executive Officer)inConstance Chang(Executive Officer)John K Freshley(Executive Officer, Director)inJeffrey A Jamison(Executive Officer)in
BoardAaron Fletcher(Director)in
Co-investorsBios PartnersInvest MichiganNovartis Venture FundVisionary VenturesInFocus Capital Partners, LLCJohnson & Johnson Innovation – JJDC+3 more
Novai applies advanced molecular and computational approaches to eye disease, supporting clinicians and researchers in translating scientific findings into patient treatment options.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesReading, GB
Prof. Francesca Cordeiro(Founder, Director & Chief Executive Officer)Prof. M. Francesca Cordeiro(Founder & CEO)MARIA FRANCESCA CORDEIRO(Director)
BoardNATALIE PANKOVA(Director)inKARL DAVID KEEGAN(Director)STEPHEN ROY PAGE(Director)
Co-investorsAnglia Capital GroupAscensionConduit ConnectSFC CapitalStartup Funding ClubThe FSE Group+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.